Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study

There are limited data on therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) patients treated with vedolizumab (VDZ). Although an exposure–response relation has been demonstrated in the post-induction phase, this relationship is more uncertain in the maintenance phase of treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Sivridaş, Merve, Creemers, Rob H., Wong, Dennis R., Boekema, Paul J., Römkens, Tessa E. H., Gilissen, Lennard P. L., van Bodegraven, Adriaan A., Loeff, Floris C., Rispens, Theo, Derijks, Luc J. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051381/
https://www.ncbi.nlm.nih.gov/pubmed/36986833
http://dx.doi.org/10.3390/pharmaceutics15030972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051381/
https://www.ncbi.nlm.nih.gov/pubmed/36986833
http://dx.doi.org/10.3390/pharmaceutics15030972

Ejemplares similares